Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials

被引：0
作者：
Lucy A. Fowkes
Dow-Mu Koh
David J. Collins
Neil P. Jerome
David MacVicar
Sue C. Chua
Andrew D. J. Pearson
机构：
[1] Royal Marsden NHS Foundation Trust,Department of Radiology
[2] Institute of Cancer Research,Cancer Research UK and EPSRC Cancer Imaging Centre
[3] Royal Marsden NHS Foundation Trust,Nuclear Medicine & PET Department
[4] Royal Marsden NHS Foundation Trust,Paediatric Drug Development Unit, Children and Young People’s Unit
来源：
Pediatric Radiology | 2015年 / 45卷
关键词：
Computed tomography; Magnetic resonance imaging; Neoplasm; Research; Clinical trials; Metabolic imaging; Children;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cancer is the leading cause of death in children older than 1 year of age and new drugs are necessary to improve outcomes. Imaging is crucial to the drug development process and assessment of therapeutic response. In adults, tumours are often assessed with CT using size criteria. Unfortunately, techniques established in adults are not necessarily applicable in children due to differing pathophysiology, ability to cooperate and increased susceptibility to ionising radiation. MRI, in particular quantitative MRI, has to date not been fully utilised in children with extracranial neoplasms. The specific challenges of imaging in children, the potential for functional imaging techniques to inform upon and their inclusion in clinical trials are discussed.
引用
收藏
页码：1600 / 1615
页数：15
相关论文
共 289 条
[1]  
Pritchard-Jones K(2013)Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries Lancet Oncol 14 e95-e103
[2]  
Pieters R(2008)Ethical, regulatory and scientific challenges in paediatric drug development Pharm Med 22 221-234
[3]  
Reaman GH(2006)Little patients, losing patience: pediatric cancer drug development Mol Cancer Ther 5 1905-1908
[4]  
Rose K(2011)The genetic landscape of the childhood cancer medulloblastoma Science 331 435-439
[5]  
Boklan J(2014)Mechanisms of neuroblastoma regression Nat Rev Clin Oncol 11 704-713
[6]  
Parsons DW(2011)Immunity over inability: the spontaneous regression of cancer J Nat Sci Biol Med 2 43-49
[7]  
Li M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[8]  
Zhang X(2007)2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group Pediatr Radiol 37 123-132
[9]  
Brodeur GM(2004)Changes in computed tomography features following preoperative chemotherapy for nephroblastoma: relation to histopathological classification Eur Radiol 14 990-994
[10]  
Bagatell R(2006)Measuring response in a post-RECIST world: from black and white to shades of grey Nat Rev Cancer 6 409-414
12345678910